Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine

about

Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine

Item

http://www.wikidata.org/entity/Q58546710

description

im November 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Is ctDNA the Road Map to the L ...... cations for Precision Medicine

@en

Is ctDNA the Road Map to the L ...... cations for Precision Medicine

@nl

type

Item

label

Is ctDNA the Road Map to the L ...... cations for Precision Medicine

@en

Is ctDNA the Road Map to the L ...... cations for Precision Medicine

@nl

prefLabel

Is ctDNA the Road Map to the L ...... cations for Precision Medicine

@en

Is ctDNA the Road Map to the L ...... cations for Precision Medicine

@nl

P1476

Is ctDNA the Road Map to the L ...... cations for Precision Medicine

@en

P2093

Rachel Schiff

http://www.w3.org/2001/XMLSchema#string

Rinath Jeselsohn

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Comprehensive molecular portraits of human breast tumours

Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis

A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer.

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date.

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.

CDK4/6 inhibition in breast cancer: current practice and future directions

P304

1352-1354

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-18-1084

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30385523

http://www.w3.org/2001/XMLSchema#string

P932

6217858

http://www.w3.org/2001/XMLSchema#string